EPS for Polaris Infrastructure Inc. (PIF) Expected At $0.04; Artal Group Sa Has Decreased Alnylam Pharmaceuticals (Call) (ALNY) Holding

April 17, 2018 - By Pete Kolinski

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Artal Group Sa decreased Alnylam Pharmaceuticals Inc (Call) (ALNY) stake by 20% reported in 2017Q4 SEC filing. Artal Group Sa sold 50,000 shares as Alnylam Pharmaceuticals Inc (Call) (ALNY)’s stock rose 5.82%. The Artal Group Sa holds 200,000 shares with $25.41 million value, down from 250,000 last quarter. Alnylam Pharmaceuticals Inc (Call) now has $9.82B valuation. The stock increased 2.32% or $2.22 during the last trading session, reaching $98.06. About 699,637 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since April 17, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Analysts expect Polaris Infrastructure Inc. (TSE:PIF) to report $0.04 EPS on May, 8.They anticipate $0.13 EPS change or 144.44% from last quarter’s $-0.09 EPS. T_PIF’s profit would be $627,013 giving it 123.81 P/E if the $0.04 EPS is correct. After having $0.06 EPS previously, Polaris Infrastructure Inc.’s analysts see -33.33% EPS growth. The stock decreased 0.40% or $0.08 during the last trading session, reaching $19.81. About 20,846 shares traded. Polaris Infrastructure Inc. (TSE:PIF) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Polaris Infrastructure Inc., a renewable energy company, acquires, explores, develops, and operates geothermal energy projects in Latin America. The company has market cap of $310.53 million. The firm owns and operates the San Jacinto project, a 72 megawatt geothermal facility that covers an area of 40 square kilometers located in northwest Nicaragua. It has a 186.89 P/E ratio. The Company’s exploration and development properties include the Casita project comprising an exploration concession with an area of 100 square kilometers located in northwest Nicaragua; Orita project located in Imperial County, California; and the Clayton Valley geothermal project located in Esmeralda County, Nevada.

Among 2 analysts covering Polaris Infrastructure (TSE:PIF), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Polaris Infrastructure had 4 analyst reports since January 8, 2016 according to SRatingsIntel. The stock has “Buy” rating by Clarus Securities on Friday, January 8. The firm earned “Buy” rating on Friday, May 20 by Mackie.

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 103 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Needham given on Wednesday, November 16. The firm has “Buy” rating by Chardan Capital Markets given on Monday, June 12. The rating was maintained by FBR Capital on Friday, February 16 with “Buy”. As per Thursday, September 21, the company rating was maintained by Needham. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Cowen & Co on Thursday, September 21. Jefferies maintained it with “Buy” rating and $58 target in Thursday, October 6 report. Jefferies initiated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Friday, October 23 with “Buy” rating. The stock has “Outperform” rating by JMP Securities on Friday, August 28. The rating was maintained by JMP Securities with “Buy” on Tuesday, April 3. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Market Perform” rating by Leerink Swann on Thursday, September 21.

Investors sentiment increased to 2.03 in Q4 2017. Its up 1.11, from 0.92 in 2017Q3. It improved, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Opus Point Prtnrs Management Limited Liability Company holds 4.73% or 43,064 shares in its portfolio. 153,270 were accumulated by Susquehanna Group Llp. Moreover, State Bank Of Montreal Can has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Eaton Vance Mgmt invested in 36,866 shares. Winfield Associates Inc accumulated 5 shares. Ckw reported 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). First Advsrs Limited Partnership has 0.17% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 571,398 shares. Segall Bryant And Hamill Limited Liability Corporation reported 2,000 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Management holds 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 11,700 shares. California-based Tarbox Family Office has invested 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). British Columbia Inv Mgmt Corp accumulated 34,505 shares. Laurion Management LP has 121,735 shares. Citadel Advsrs Ltd Liability Corporation accumulated 57,507 shares or 0% of the stock. Assetmark stated it has 0% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Wells Fargo & Company Mn reported 124,298 shares.

Since January 4, 2018, it had 0 insider buys, and 10 insider sales for $38.04 million activity. On Tuesday, March 13 Ausiello Dennis A sold $2.57M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 17,117 shares. Another trade for 7,221 shares valued at $985,958 was made by Greenstreet Yvonne on Monday, March 26. Another trade for 15,000 shares valued at $1.94 million was sold by SHARP PHILIP A. Another trade for 20,000 shares valued at $2.90 million was sold by KEATING LAURIE. $12.67M worth of stock was sold by Vaishnaw Akshay on Wednesday, March 14. On Wednesday, March 14 Greene Barry E sold $5.50 million worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 38,460 shares. On Thursday, January 4 the insider Mason Michael sold $4.84M.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 4. They expect $-1.48 EPS, down 18.40% or $0.23 from last year’s $-1.25 per share. After $-1.48 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>